RWD ‘Health’ Steps for Pharma


How FDA’s new steering on real-world information reshapes vital “fit-for-purpose” evaluations

Matthew W. Reynolds, vice chairman, real-world options, at IQVIA, dives into the implications of FDA’s current draft steering on utilizing real-world information from digital well being data and medical claims information to assist in drug improvement and regulatory decision-making—and shares particular steps pharma firms can take to evaluate the relevance and high quality of their information in gentle of this steering.

The most recent episode of The Pharmaceutical Commerce Podcast is obtainable immediately on SoundCloud.



Supply hyperlink